Answers are grounded in this paper and cite their sources.
Aim Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
No takes yet. Share an insight, caveat, or question.
Maillard et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: